---
title: "ZHEZHONG has repurchased 5% of its shares at a cost of 241 million yuan"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/255584714.md"
description: "According to the Zhitong Finance APP, ZHEZHONG announced that as of August 31, 2025, the company repurchased 22.1001 million shares through a special securities repurchase account via centralized bidding, accounting for 5% of the company's total share capital, with a maximum transaction price of 11.5 yuan/share, a minimum transaction price of 9.44 yuan/share, and a total transaction amount of 241 million yuan (excluding transaction fees)"
datetime: "2025-09-02T09:42:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/255584714.md)
  - [en](https://longbridge.com/en/news/255584714.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/255584714.md)
generator: "portal-rs"
---

# ZHEZHONG has repurchased 5% of its shares at a cost of 241 million yuan

According to the Zhitong Finance APP, ZHEZHONG (002346.SZ) announced that as of August 31, 2025, the company repurchased 22.1001 million shares through a dedicated securities repurchase account via centralized bidding, accounting for 5% of the company's total share capital, with a maximum transaction price of 11.5 yuan/share, a minimum transaction price of 9.44 yuan/share, and a total transaction amount of 241 million yuan (excluding transaction fees)

### Related Stocks

- [002346.CN](https://longbridge.com/en/quote/002346.CN.md)

## Related News & Research

- [Palvella Therapeutics COO Kathleen Goin reports sale of 4,302 common shares worth $654,184.41](https://longbridge.com/en/news/296530942.md)
- [Tech tries a new message: You'd love data centers if China wasn't making you hate data centers](https://longbridge.com/en/news/296638983.md)
- [Multicoin Capital-Linked Wallet Transfers 197,560 HYPE to CEX, Raising Sale Concerns](https://longbridge.com/en/news/296661501.md)
- [08:56 ETMarco's Pizza Ranks as a Top Franchise Brand on 2026 QSR 50 List](https://longbridge.com/en/news/296495239.md)
- [Tvardi Therapeutics: TTI-109, an oral STAT3 inhibitor, targets unmet needs in UC with promising safety and efficacy data](https://longbridge.com/en/news/296388332.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**